The United Kingdom early Mitoxantrone Copaxone trial is a controlled study which will compare combination therapy with mitoxantrone and Glatiramer Acetate (Copaxone) against high dose interferon beta treatment (Rebif 44).
The trial began in May 2005 and is looking to recruit a total of 60 people with relapsing remitting MS from across the UK.
The trial aims to identify better treatment approaches for people with "active" relapsing remitting MS.
If you have a definite diagnosis of relapsing remitting MS and had your first symptoms less than five years ago you may be eligible to enter the trial. You must have experienced 2 relapses in the last two years and not be receiving disease modifying therapy for your condition in order to participate.
Unfortunately, if you have secondary progressive or primary progressive MS you will not be eligible to participate in this trial, as this combination of treatments has not been shown to be effective in progressive forms of MS.